JNETS clinical practice guidelines for gastroenteropancreatic neuroendocrine neoplasms: diagnosis, treatment, and follow-up: a synopsis.

"Declarations Conflict of interestAny financial relationship with enterprises, businesses, or academic institutions in the subject matter or materials discussed in the manuscript are listed as follows; Tetsuhide Ito received speaker’s honoraria from Teijin Pharma Limited, Novartis Pharma and Mylan EPD. Robert Y. Osamura received speaker’s honoraria from Teijin Pharma Limited and Novartis Pharma. Akihiro Sakurai received speaker’s honoraria from AstraZeneca. Masafumi Ikeda received speaker’s honoraria from Novartis Pharma, Chugai Pharmaceutical Co. Ltd. and Bayer Pharma. Susumu Hijioka received speaker’s honoraria from Teijin Pharma Limited, Novartis Pharma and Novel Pharma. Taku Aoki received speaker’s honoraria from Novartis Pharma. Atsuko Kasajima received speaker’s honoraria from Teijin Pharma Limited. Ryoji Kushima received speaker’s honoraria from Takeda Pharmaceutical Co. Ltd. Hironobu Sasano received speaker’s honoraria from Novartis Pharma. Tsuyoshi Konishi received speaker’s honoraria from Olympus and Johnson & Johnson. The authors, the spouse, partner or immediate relatives of the authors report no other conflicts of interest in this work. Conflict of interest Any financial relationship with enterprises, businesses, or academic institutions in the subject matter or materials discussed in the manuscript are listed as follows; Tetsuhide Ito received speaker’s honoraria from Teijin Pharma Limited, Novartis Pharma and Mylan EPD. Robert Y. Osamura received speaker’s honoraria from Teijin Pharma Limited and Novartis Pharma. Akihiro Sakurai received speaker’s honoraria from AstraZeneca. Masafumi Ikeda received speaker’s honoraria from Novartis Pharma, Chugai Pharmaceutical Co. Ltd. and Bayer Pharma. Susumu Hijioka received speaker’s honoraria from Teijin Pharma Limited, Novartis Pharma and Novel Pharma. Taku Aoki received speaker’s honoraria from Novartis Pharma. Atsuko Kasajima received speaker’s honoraria from Teijin Pharma Limited. Ryoji Kushima received speaker’s honoraria from Takeda Pharmaceutical Co. Ltd. Hironobu Sasano received speaker’s honoraria from Novartis Pharma. Tsuyoshi Konishi received speaker’s honoraria from Olympus and Johnson & Johnson. The authors, the spouse, partner or immediate relatives of the authors report no other conflicts of interest in this work."